BeOne Medicines Wins HKCT Business Award

BeOne Medicines, a global oncology company, was named 'Outstanding Global Oncology Company of the Year' at the HKCT Business Awards 2026, organized by the Hong Kong Commercial Times. This award acknowledges BeOne Medicines' significant progress in research, development, and manufacturing of innovative cancer therapies, as well as its efforts to enhance patient access to medicines. Richard Cheng, Associate Commercial Director at BeOne Medicines, highlighted the company's plans to expand its operations in China — Hong Kong, leveraging local policies and the upcoming China — Hong Kong Centre for Medical Products Regulation. BeOne Medicines' R&D platform has advanced over 35 clinical-stage drug candidates, with three internally developed products commercially approved, reaching more than 2 million patients globally. The company's pipeline includes a BTK Inhibitor, a PD-1 Inhibitor approved for six indications in China — Hong Kong, and a Next-Generation BCL-2 Inhibitor that received Priority Review from the United States — Food and Drug Administration and has a marketing application submitted in the European Union. BeOne Medicines maintains manufacturing sites in the United States (New Jersey) and China (Suzhou and Guangzhou) to support its global supply network.